You are viewing: Asia Pacific Latent TB Testing Market analysis
Part of: Latent TB Testing Market (Global)

The Asia Pacific Latent TB Testing Market was valued at $202.8 Million in 2024 and projected to reach to $298.7 Million by 2029, representing a compound annual growth rate of 8.1%. The Asia Pacific latent TB testing market is positioned for sustained expansion through 2029, supported by escalating TB burden in high-prevalence countries and strengthened healthcare infrastructure investments.

Asia Pacific Latent TB Testing Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Asia Pacific Latent TB Testing Market Trends and Insights

  • Asia Pacific's market expansion is driven by rising TB prevalence, increasing healthcare investments, and growing awareness of latent TB infection screening across the region.
  • The 8.1% compound annual growth rate in Asia Pacific significantly outpaces global trends, reflecting the region's critical need for diagnostic solutions and strengthened public health infrastructure. Asia Pacific's latent TB testing market benefits from demographic factors, including large at-risk populations and improving access to healthcare facilities.
  • Between 2024 and 2029, Asia Pacific is expected to see accelerated adoption of advanced testing technologies, including interferon-gamma release assays and tuberculin skin tests.
  • Government initiatives and WHO-supported TB elimination programs are further catalyzing market penetration across Asia Pacific, positioning the region as a key growth engine for the global latent TB testing industry..

Key Market Statistics

  • CAGR (2024-2029) 8.1% CAGR
  • Market Size, 2024 ~USD 202.8 Million
  • Forecast, 2029 ~USD 298.7 Million
  • Geography Asia Pacific

Asia Pacific Latent TB Testing Market Overview

Strong Regional Growth Trajectory :

Asia Pacific latent TB testing market is expanding at 8.1% CAGR, outpacing the global rate of 5.8%, driven by rising TB prevalence and increased healthcare investments across the region.

Market Valuation & Expansion :

The market is valued at $202.8 million in 2024 and is projected to reach $298.7 million by 2029, representing a 47% increase over the five-year forecast period.

China & Japan Lead Regional Demand :

China ($143.05M) and Japan ($68.15M) are the dominant markets in Asia Pacific, collectively accounting for over 80% of regional latent TB testing market value.

Growing Awareness & Screening Initiatives :

Increased awareness of latent TB infection screening and government-backed public health programs are accelerating adoption of diagnostic testing across Asia Pacific healthcare systems.

Asia Pacific Latent TB Testing Market Dynamics

  • China, Japan, and India are driving significant demand through enhanced diagnostic capabilities and screening programs.
  • Government initiatives targeting TB elimination, coupled with rising healthcare expenditure and improved access to testing technologies, are creating favorable conditions for market growth.
  • The region's 8.1% CAGR reflects both the clinical urgency of latent TB management and increasing adoption of advanced diagnostic solutions across diverse healthcare settings..

Related Ecosystem

Medical Devices

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Magnetic Resonance Imaging (MRI)
  • Disposable Autoinjectors
  • Pulse Oximeters
  • Blood Pressure Monitors
Top Companies
  • Medtronic plc
  • Abbott Laboratories
  • Stryker Corporation
  • Becton, Dickinson and Company
  • CONMED Corporation

    Key Takeaways

    • Asia Pacific latent TB testing market valued at $202.8M in 2024, expanding to $298.7M by 2029 at 8.1% CAGR
    • Asia Pacific's growth rate outpaces global average, driven by high TB burden and healthcare infrastructure improvements
    • Asia Pacific adoption of IGRAs and TST technologies accelerating due to government TB elimination programs
    • Asia Pacific represents critical growth opportunity with large at-risk populations and increasing diagnostic awareness

    Latent TB Testing Market Report Scope

    Report Metric Details
    Base Year 2024
    Fastest Growing Segment HOUSEHOLD CONTACTS WITH PULMONARY TB (Application)
    Forecast Period 2024-2029
    Growth Rate CAGR of 5.8% from 2024 to 2029
    Largest Segment IGRA (Test Type)
    Market Size Base Year (Billions) ~USD 0.58 (2024)
    Revenue Forecast (Billions) ~USD 0.77 (2029)
    Segments Covered Test Type, Application, End User

    Asia Pacific Latent TB Testing Market Report Segmentation

    3 segment dimensions are covered across the global market.

    By Test Type

    • Igra
    • Tst

    By Application

    • Household Contacts With Pulmonary Tb
    • Other Applications
    • People Living With Hiv

    By End User

    • Academic & Research Institutes
    • Diagnostic Laboratories
    • Hospitals & Clinics
    • Other End Users

    Target Audience

    • Diagnostic Device Manufacturers : Evaluate market size, growth potential, and competitive dynamics in Asia Pacific to guide product development, commercialization, and market entry strategies for latent TB testing solutions.
    • Healthcare Providers & Hospital Networks : Understand regional demand trends and market forecasts to optimize latent TB screening program investments and align diagnostic capabilities with patient population needs.
    • Pharmaceutical & Biotech Companies : Assess Asia Pacific market opportunities for TB treatment and prevention therapies by analyzing latent TB testing prevalence, screening rates, and patient identification trends.
    • Healthcare Investors & Private Equity : Evaluate investment opportunities in Asia Pacific TB diagnostics and healthcare infrastructure by analyzing market growth rates, regional valuations, and expansion potential.
    • Government & Public Health Agencies : Leverage market data to inform TB elimination strategies, screening program budgeting, and healthcare resource allocation across Asia Pacific regions and countries.

    Asia Pacific vs. other regions

    HowAsia Pacific compares to the other 3 regional blocs covered in this market.

    North America
    ~USD 239.8 Million · 2.8% wtd CAGR ·
    Europe
    ~USD 183.6 Million · 6.5% wtd CAGR ·
    Latin America
    ~USD 44.9 Million · 7.4% wtd CAGR ·
    Middle East & Africa
    ~USD 6.4 Million · 5.7% wtd CAGR ·

    Countries within Asia Pacific - compare and drill down

    Country2025 size (native)
    ChinaUSD 143.05 Million
    IndiaUSD 42.42 Million
    JapanUSD 68.15 Million
    South KoreaUSD 12.94 Million
    AustraliaUSD 6.46 Million
    SingaporeUSD 4.09 Million
    BangladeshUSD 0.51 Million

    Country market size visualization

    China
    USD 143.05 Million
    India
    USD 42.42 Million
    Japan
    USD 68.15 Million
    South Korea
    USD 12.94 Million
    Australia
    USD 6.46 Million
    Singapore
    USD 4.09 Million
    Bangladesh
    USD 0.51 Million

    Reasons to Buy this Report

    • Regional Market Sizing & Forecasts : Obtain precise market valuations for Asia Pacific ($202.8M in 2024) and country-level breakdowns for China, Japan, India, and other key markets to inform strategic planning.
    • Growth Driver Analysis : Understand the specific factors accelerating the 8.1% CAGR in Asia Pacific, including TB prevalence trends, healthcare policy changes, and investment patterns unique to the region.
    • Competitive Landscape Intelligence : Identify leading diagnostic providers, emerging players, and market consolidation trends specific to Asia Pacific latent TB testing to benchmark competitive positioning.
    • Country-Level Market Opportunities : Access detailed insights into individual Asia Pacific markets (China, Japan, India, South Korea, Australia, Singapore) to prioritize market entry and expansion strategies.
    • Regulatory & Healthcare System Insights : Gain understanding of regional regulatory frameworks, reimbursement models, and healthcare system dynamics that influence latent TB testing adoption across Asia Pacific.

    Frequently asked questions

    What is the current size of the latent TB testing market in Asia Pacific?

    The Asia Pacific latent TB testing market was valued at $202.8 million in 2024 and is projected to reach $298.7 million by 2029.

    What is the CAGR for latent TB testing in Asia Pacific?

    Asia Pacific's latent TB testing market is growing at a compound annual growth rate of 8.1% from 2024 to 2029.

    Why is Asia Pacific's latent TB testing market growing faster than the global average?

    Asia Pacific's higher growth rate is driven by elevated TB prevalence, expanding healthcare infrastructure, government TB elimination initiatives, and increasing diagnostic awareness across the region.

    Which testing technologies are driving growth in Asia Pacific's latent TB market?

    Interferon-gamma release assays (IGRAs) and tuberculin skin tests (TST) are the primary technologies driving adoption in Asia Pacific, supported by WHO-backed screening programs.

    What factors are expected to sustain latent TB testing demand in Asia Pacific through 2029?

    Sustained demand in Asia Pacific is expected from large at-risk populations, government TB control programs, improved healthcare access, and rising clinical awareness of latent TB infection screening benefits.

    RESEARCH METHODOLOGY

    The study involved major activities in estimating the current market size for the latent TB testing market. Exhaustive secondary research was done to collect information on the latent TB testing industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the latent TB testing market.

    The four steps involved in estimating the market size are

    Secondary Research

    In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

    The following is a breakdown of the primary respondents:

    Note 1: Others include sales managers, marketing managers, and product managers.

    Note 2: Companies are classified into tiers based on their total revenues. As of 2022/2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

    To know about the assumptions considered for the study, download the pdf brochure

    COMPANY NAME DESIGNATION
    QIAGEN General Manager
    Revvity Area Sales Manager

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the latent TB testing market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry have been identified through extensive secondary research
    • The revenues generated by leading players operating in the latent TB testing market have been determined through primary and secondary research.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    The research methodology used to estimate the market size includes the following:

    Data Triangulation

    After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Latent tuberculosis testing refers to diagnosing the infection by detecting an immune response to Mycobacterium tuberculosis antigens using either the tuberculin skin test (TST) or interferon-gamma release assays (IGRAs). These tests help identify dormant tuberculosis infections in individuals without active symptoms.

    Stakeholders

    • Senior Management
    • End User
    • Finance/Procurement Department  
    • R&D Department

    Report Objectives

    • To define, describe, segment, and forecast the global latent TB testing market, by test type, application, end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall latent TB testing market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Middle East & Africa, and Latin America
    • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
    • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence

     

    Get the Full Latent TB Testing Market Report

    Full forecast, segment splits, and company analysis for all Latent TB Testing Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status